Skip to main content
. Author manuscript; available in PMC: 2018 Jan 18.
Published in final edited form as: Vaccine. 2009 Feb 5;27(25-26):3484–3488. doi: 10.1016/j.vaccine.2009.01.047

Fig. 3.

Fig. 3

Poor presentation of nanoparticle formulated αGalCer by B cells. B220 + B cells were purified from mouse spleen by cell sorting. 200,000 B cells were mixed with different concentration of nanoparticle formulated αGalCer, and incubated with 100,000 NKT cells (DN32.D3) for 24 h.NKT cell activation was represented by their secretion of cytokine (IL2). CD11c + cells and CD11b + cells were studied in parallel. Data were representative of two independent experiments: (A) presentation of nanoparticle formulated αGalCer and (B) presentation of free αGalCer.